Sumitomo Mitsui Trust Group Inc. Sells 801,804 Shares of Recursion Pharmaceuticals, Inc. $RXRX

Sumitomo Mitsui Trust Group Inc. trimmed its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 12.9% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 5,419,221 shares of the company’s stock after selling 801,804 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Recursion Pharmaceuticals were worth $16,637,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. International Assets Investment Management LLC bought a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at about $31,000. Integral Investment Advisors Inc. bought a new position in Recursion Pharmaceuticals during the 1st quarter worth about $39,000. Sequoia Financial Advisors LLC purchased a new position in Recursion Pharmaceuticals during the 4th quarter valued at about $41,000. MQS Management LLC purchased a new position in Recursion Pharmaceuticals during the 1st quarter valued at about $41,000. Finally, Allworth Financial LP raised its holdings in shares of Recursion Pharmaceuticals by 85.6% in the 3rd quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock valued at $47,000 after purchasing an additional 4,403 shares in the last quarter. Institutional investors own 89.06% of the company’s stock.

Insider Activity at Recursion Pharmaceuticals

In related news, CEO Najat Khan sold 23,588 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $3.58, for a total transaction of $84,445.04. Following the completion of the sale, the chief executive officer owned 2,175,796 shares of the company’s stock, valued at $7,789,349.68. This represents a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $3.96, for a total transaction of $158,400.00. Following the completion of the sale, the director owned 6,218,287 shares of the company’s stock, valued at approximately $24,624,416.52. This trade represents a 0.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 131,937 shares of company stock valued at $486,974. 6.65% of the stock is currently owned by company insiders.

Recursion Pharmaceuticals Stock Performance

Shares of Recursion Pharmaceuticals stock opened at $3.34 on Wednesday. The company has a market capitalization of $1.77 billion, a PE ratio of -2.78 and a beta of 1.00. The company has a 50-day simple moving average of $3.34 and a two-hundred day simple moving average of $3.62. Recursion Pharmaceuticals, Inc. has a one year low of $2.77 and a one year high of $7.18. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.47 and a current ratio of 5.47.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. The business had revenue of $6.47 million for the quarter, compared to analysts’ expectations of $15.78 million. During the same period last year, the business earned ($0.50) EPS. The company’s revenue was down 56.8% compared to the same quarter last year. Research analysts expect that Recursion Pharmaceuticals, Inc. will post -0.99 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Morgan Stanley upped their price target on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a research report on Thursday, May 14th. JPMorgan Chase & Co. cut their price objective on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a report on Thursday, April 30th. Needham & Company LLC reissued a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Tuesday, April 21st. Finally, Wall Street Zen cut Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $8.10.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.